Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $226.76M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.95M
Average 1.29M
VNDA Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $68.36M rose 36.5% year over year, behind the +54.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at +20.4% a year.
Context
- Selling, general & admin amounted to 110.1% of revenue in FY2025, up 36.4 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $165.71M (-30.4%) for the fiscal year ending Dec 2026, a slowdown from the +62.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $68.36M+8.5% QoQ
- Last fiscal yearDec 2025
- $237.95M+62.5% YoY
- LTMMar 2026
- $256.23M+54.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 237.95M USD
- Year-over-year change
- +62.5%
- 4-year CAGR
- +17.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 237.95M | +62.5% |
| FY2024 | 2024-12-31 | 146.41M | +29.7% |
| FY2023 | 2023-12-31 | 112.88M | -17.3% |
| FY2022 | 2022-12-31 | 136.49M | +10.0% |
| FY2021 | 2021-12-31 | 124.05M | — |
Selling, General & Admin vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's LTM Mar 2026 selling, general & admin of $256.23M is the 2nd highest of the 11 companies compared; the peer median is $34.68M.
- Its year-over-year change of +54.0% is the 4th highest of 11, against a peer median of +0.9%.
- Selling, general & admin amounts to 117.7% of revenue for VNDA, versus a peer median of 405.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.7B | +29505.3% | +3.5% | — | |
| LTM Mar 2026 | $256.23M | +54.0% | +20.4% | 117.7% | |
| LTM Mar 2026 | $55.88M | -11.2% | -10.5% | — | |
| LTM Mar 2026 | $43.57M | -11.6% | +0.0% | 96.1% | |
| LTM Mar 2026 | $40.9M | +4.0% | +10.2% | 712.8% | |
| LTM Mar 2026 | $36.17M | -2.1% | +6.6% | 99.1% | |
| LTM Mar 2026 | $33.2M | +76.0% | +43.8% | — | |
| LTM Mar 2026 | $30.28M | -34.0% | -12.3% | — | |
| LTM Mar 2026 | $27.31M | -10.2% | +10.9% | 1354.8% | |
| LTM Mar 2026 | $26.76M | +58.7% | +29.7% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $18.03M | +5.9% | +42.7% | — |
| Peer median (excluding VNDA) | $34.68M | +0.9% | +8.4% | 405.9% | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 268.68M | 254.38M | 192.64M | 198.77M | 216.11M |
| Cost of Revenue | 25.63M | 24.28M | 14.8M | 11.31M | 13.04M |
| Gross Profit | 243.05M | 230.1M | 177.84M | 187.46M | 203.06M |
| Gross Margin | 90.5% | 90.5% | 92.3% | 94.3% | 94.0% |
| Research & Development | 75.36M | 85.77M | 76.82M | 74.43M | 109.27M |
| Selling, General & Admin | 124.05M | 136.49M | 112.88M | 146.41M | 237.95M |
| Operating Expenses | 200.89M | 223.77M | 191.8M | 228.12M | 354.23M |
| Depreciation & Amortization | 2.84M | 2.73M | 3.01M | 8.13M | 11.92M |
| EBITDA | 45.21M | 14.03M | 9.35M | (14.79M) | (126.73M) |
| EBITDA Margin | 16.8% | 5.5% | 4.9% | -7.4% | -58.6% |
| Operating Income | 42.17M | 6.33M | (13.95M) | (40.66M) | (151.17M) |
| Operating Margin | 15.7% | 2.5% | -7.2% | -20.5% | -70.0% |
| Interest Income | 199K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 199K | 4.97M | 20.29M | 17.74M | 12.52M |
| Income Before Tax | 42.36M | 11.3M | 6.34M | (22.92M) | (138.65M) |
| Pre-Tax Margin | 15.8% | 4.4% | 3.3% | -11.5% | -64.2% |
| Income Tax Expense | 9.21M | 5.03M | 3.83M | (4.02M) | 81.83M |
| Net Income | 33.15M | 6.28M | 2.51M | (18.9M) | (220.47M) |
| Net Margin | 12.3% | 2.5% | 1.3% | -9.5% | -102.0% |
| EPS (Basic) | 0.60 | 0.11 | 0.04 | (0.32) | (3.74) |
| EPS (Diluted) | 0.58 | 0.11 | 0.04 | (0.32) | (3.74) |
| Weighted Avg Shares | 55.55M | 56.46M | 57.38M | 58.15M | 58.93M |
| Weighted Avg Shares (Diluted) | 56.92M | 56.98M | 57.56M | 58.15M | 58.93M |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.